Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Menorrhagia Clinical Trial

Official title:

A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03642210
• Other study ID #: M360-L105
• Status: Completed
• Phase: Phase 3
• Start date: January 17, 2019
• Est. completion date: October 12, 2021

Study information

• Verified date: April 2024
• Source: Medicines360
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy menstrual bleeding.

Description:

This study is a multicenter, open-label, evaluation of the efficacy and safety of LNG20 IUS for treatment of heavy menstrual bleeding.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: October 12, 2021
• Est. primary completion date: October 12, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Signed informed consent

• Reports subjectively heavy menses for most menses when not using hormonal contraception or a copper IUD

• Healthy females 18-50 years old, inclusive, at the time of enrollment

• Able to read and write, as determined by study personnel

• FSH value =30 mIU/mL at screening

• Typical menstrual cycle length of 21-35 days with variation from cycle to cycle of typically 5 days or less

• Has menstrual blood loss in 2 of the 3 cycles during the Screening Phase with = 80 mL per cycle as measured by the AH method

• Uterine sound depth of =5.5 cm

• Willing to comply with study visit schedule and assessments, including sanitary product collection and diary completion requirements

• Documented (i.e., printed report) Pap testing, regardless of subject's age, and any indicated evaluation/treatment that demonstrates no need for further evaluation during the course of study participation (i.e., within 10 months after consent)

• Planning to reside within a reasonable driving distance of a research site (approximately 150 miles) for duration of study participation

• Willing to use a medication other than a NSAID as first-line treatment for any pain condition during the duration of study participation

• Willing to abstain from heterosexual intercourse or use acceptable contraception during the screening phase; acceptable contraception includes male or female permanent contraception, withdrawal (if has been using as current method prior to screening) or a barrier method

• If previously pregnant, at least one subjectively heavy menses prior to screening

Exclusion Criteria:

• Currently pregnant

• Planning to attempt to become pregnant during the screening and treatment phases of study participation (i.e., up to approximately 11 months after consent)

• Currently lactating or not having a subjectively heavy menses since discontinuation of lactation prior to screening

• Clinical diagnosis of perimenopause (in the opinion of the investigator) based on one or more of the following: changes in menstrual regularity (e.g., shorter, longer, absent, irregular), hot flashes, sleeping disorder, or changes in mood (e.g., depression, nervous tension, and irritability) within 3 months prior to or during the screening period

• Screening blood laboratory value outside of the normal range that, in the opinion of the investigator, requires treatment or further work-up (i.e., are considered clinically significant)

• Has poor venous access or significant history of inability to have blood samples drawn

• Body habitus or history of lower genital tract abnormalities or prior surgeries which may prohibit proper visualization of the cervix or not allow the uterus to be appropriately instrumented

• History of bicornuate uterus or any other abnormality of the uterus resulting in distortion of the uterine cavity or cervical canal incompatible with insertion

• Prior (documented within 6 months) or baseline study ultrasound examination demonstrating:

• A congenital or acquired uterine anomaly that distorts the uterine cavity or cervical canal incompatible with insertion;

• Endometrial polyps (unless previously removed),

• Fibroids meeting any of the following criteria: Distort the uterine cavity or cervical canal incompatible with insertion; Submucosal location; Exceeding 2 cm in the greatest dimension for any individual fibroid; More than three fibroids of at least 1.5 cm in greatest diameter

• Clear evidence of adenomyosis consisting of any of the following: Subendometrial cysts; Diffuse adenomyosis based on a heterogeneous myometrial echotexture consisting of Hyperechoic findings (islands of endometrial glands), hypoechoic findings (associated muscle hypertrophy), or "Venetian blind" appearance due to subendometrial echogenic linear striations and acoustic shadowing where endometrial tissues cause a hyperplastic reaction.

• Recently diagnosed or clinically evident cervicitis or upper genital tract infection at the time of IUS insertion (unless successfully treated and considered clinically cured for at least 7 days prior to enrollment)

• History of pelvic actinomycosis infection (i.e., received antibiotic treatment; criterion does not include solely a history of Pap test with actinomyces)

• Postpartum or post-abortion endometritis unless symptoms resolved at least 4 weeks prior to screening

• Chronic endometritis on endometrial biopsy at screening (an endometrial biopsy performed within 6 months of Visit 1 could be used if a report is available with a tissue diagnosis)

• Has any of the following premalignant or malignant diseases:

• Malignant melanoma

• Acute malignancies affecting blood or leukemias

• Gestational trophoblastic disease (unless at least one year with undetectable beta-hCG)

• Known or suspected cervical, ovarian, vaginal or vulvar cancer

• Uterine cancer or evidence of uterine malignancy, endometrial intraepithelial neoplasia (EIN) or hyperplasia on an endometrial biopsy at screening (an endometrial biopsy performed within 6 months of Visit 1 could be used if a report is available with a tissue diagnosis)

• History of breast cancer, or suspicion of breast cancer until proven otherwise

• Has any of the following medical conditions:

• Bleeding diathesis (inherited or acquired)

• History of von Willebrand's disease or other known coagulopathy

• Uncontrolled significant hypertension defined as a sitting systolic blood pressure = 160 mm Hg or diastolic blood pressure = 95 mm Hg at any screening or enrollment visit unless treated and controlled within two weeks of discovery

• Presence or history of venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), presence or history of arterial thromboembolic diseases (e.g., myocardial infarction, stroke)

• Uncontrolled thyroid disorder

• Sickle cell anemia

• Diabetes mellitus that is poorly controlled or with end-organ/vascular complications

• Hyperprolactinemia at screening

• Acute or severe liver disease or liver tumor

• Poorly controlled bipolar disorder, schizophrenia, psychosis, major depressive disorder or other major psychiatric disorder according the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-5)

• History of a positive HIV test or having a partner who is known to be HIV positive

• Current or history of alcohol, illicit drug or prescription drug abuse within 12 months prior to screening

• Use of antifibrinolytics, platelet aggregation inhibitors, anticoagulants or other similar medications that can increase or decrease bleeding within 30 days prior to and during the screening (EXCEPTION: NSAIDs can be used as second-line treatment for pain management)

• Use of intrauterine or implantable contraception, progestin-only pills, combined hormonal contraceptives or oral progestin therapy within 30 days before screening

• Depomedroxyprogesterone acetate (DMPA) injection within the past 9 months prior to screening (this exclusionary time period can be shortened to 6 months if the subject has also had two spontaneous menstrual cycles [requires minimum of 3 heavy menses] that meet criteria for normal menstrual cycle pattern)

• Use of non-contraceptive estrogen, progesterone, progestin, testosterone, androgen or other gonadotropins (e.g. hCG) within 30 days before screening

• Prior total or partial endometrial ablation or resection

• History of a uterine aspiration or curettage procedure for any indication (other than an office biopsy) within 4 weeks of screening

• Known or suspected allergy to levonorgestrel or hypersensitivity to any component of the product

• Use of an experimental medication or receipt of an experimental treatment for any condition within 30 days of screening

• Study staff or a member of the immediate family of a study staff

• Any condition or circumstance that, in the opinion of the Investigator, would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol, such as any concurrent medical condition that is not stable and well-controlled, that is likely to worsen, or that may require recurrent hospitalizations during study participation

Related Conditions & MeSH terms

• Menorrhagia

Intervention

Combination Product:
• Levonorgestrel 52 mg intrauterine system
Levonorgestrel 52 mg intrauterine system

Locations

Country	Name	City	State
United States	University of Michigan Women's Hospital	Ann Arbor	Michigan
United States	Emory University School of Medicine	Atlanta	Georgia
United States	University of Colorado Denver	Aurora	Colorado
United States	Johns Hopkins Bayview Medical Center	Baltimore	Maryland
United States	WR-ClinSearch, LLC	Chattanooga	Tennessee
United States	University of Cincinnati Physicians Company	Cincinnati	Ohio
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	The Ohio State University	Columbus	Ohio
United States	Baylor College of Medicine	Houston	Texas
United States	CR Prime	Idaho Falls	Idaho
United States	UF Health Women's Specialists	Jacksonville	Florida
United States	University of Tennessee Medical Center	Knoxville	Tennessee
United States	Rex Garn Mabey	Las Vegas	Nevada
United States	Women's Health Research Center	Lawrenceville	New Jersey
United States	WR-Medical Research Center of Memphis	Memphis	Tennessee
United States	Eastern Virginia Medical-Conrad Clinical Research Center	Norfolk	Virginia
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Magee-Womens Hospital, Center for Family Planning	Pittsburgh	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	M3 Wake Research, Inc.	Raleigh	North Carolina
United States	OB/GYN Research, University of California, Davis Health	Sacramento	California
United States	Washington University in St. Louis School of Medicine	Saint Louis	Missouri
United States	University of Utah	Salt Lake City	Utah
United States	Wr-McCr, Llc	San Diego	California
United States	WR-Mount Vernon Clinical Research, LLC	Sandy Springs	Georgia
United States	MomDoc Women's Health Research	Scottsdale	Arizona
United States	Stanford University Medical Center, OB-GYN Clinic	Stanford	California
United States	Comprehensive Clinical Trials, LLC	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Medicines360

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Successful Treatment of Heavy Menstrual Bleeding	Number of participants who completed treatment with an End-of-Treatment menstrual blood loss of <80 ml or =50% of baseline	6 months
Secondary	Menstrual Blood Loss - Percent Change From Baseline to Cycle 3 (28 Days Per Cycle; Approximately 3 Months)	• Percent change from Baseline MBL to mid-treatment MBL Cycle 3 (28 days per cycle; approximately 3 months)	3 months
Secondary	Menstrual Blood Loss - Absolute Change in Baseline to Cycle 3 (28 Days Per Cycle; Approximately 3 Months)	• Absolute change in Baseline MBL to mid-treatment MBL Cycle 3 (28 Days Per Cycle; Approximately 3 Months)	3 months
Secondary	Menstrual Blood Loss - Absolute Change From Baseline to Cycle 6 (28 Days Per Cycle; Approximately 6 Months)	• Absolute change from Baseline to end-of-treatment MBL Cycle 6 (28 Days Per Cycle; Approximately 6 Months)	6 months
Secondary	Menstrual Blood Loss - Percent Change From Baseline to Cycle 6 (28 Days Per Cycle; Approximately 6 Months)	• Percent change from Baseline MBL to end-of-treatment MBL Cycle 6 (28 Days Per Cycle; Approximately 6 Months)	6 months
Secondary	Change in Bleeding/Spotting Days From Baseline, Cycle 3, and Cycle 6.	Number of days bleeding, spotting, and bleeding and/or spotting at Baseline, Cycle 3 (approximately 3 months), and Cycle 6 (approximately 6 months).	6 months
Secondary	Blood Changes - Hemoglobin	• Percent change in hemoglobin from Baseline to mid-treatment (approximately 3 months), from Baseline to end-of-treatment (approximately 6 months), and from mid-treatment to end-of-treatment (approximately 3 months).	6 months
Secondary	Blood Changes - Hematocrit	• Percent change in hematocrit from Baseline to mid-treatment (approximately 3 months), from Baseline to end-of-treatment (approximately 6 months), and from mid-treatment to end-of-treatment (approximately 3 months).	6 months
Secondary	Blood Changes - Ferritin	Change in serum ferritin from Baseline to mid-treatment (approximately 3 months) and to end-of-treatment (approximately 6 months).	6 months
Secondary	Number of Participants That Discontinued vs Completed Full Treatment Duration	Number of Participants that Discontinued vs Completed Full Treatment Duration.	6 months
Secondary	Participant Subjective Assessments	• Subjective assessment of menstrual bleeding changes based on VAS questionnaires of Safety and Continuation Rates from Baseline to Treatment Cycle 3 (approximately 3 months) to Cycle 6 (approximately 6 months). Participants responded to various questions regarding their menstrual bleeding on Visual Analog Scales (VAS), with "Not Acceptable" at 0 cm and "Completely Acceptable" at 10 cm.	6 months
Secondary	Changes in Number of Bleeding Episodes	• Changes from Baseline to mid-treatment Cycle 3 (approximately 3 months), from Baseline to end of treatment Cycle 6 (approximately 6 months), and from mid-treatment Cycle 3 to end of treatment Cycle 6 in the number of bleeding episodes. Bleeding episodes are defined as all bleeding days separated by no more than one bleeding-free day.	6 months